Keyphrases
Calreticulin
100%
Cyclin-dependent Kinase Inhibitor 2A (CDKN2A)
100%
CDKN2B
100%
Efferocytosis
100%
Atherosclerotic Plaque
66%
Necrotic Core
66%
Genetic Variation
33%
Lipids
33%
Cardiovascular Disease
33%
Apoptosis
33%
Inflammatory Cytokines
33%
Macrophages
33%
Risk Allele
33%
Risk Loci
33%
Phagocytic Cells
33%
Reduced Expression
33%
Foam Cell Formation
33%
Atherogenesis
33%
9p21
33%
Chromosome 9p21
33%
Mouse Model of Atherosclerosis
33%
Juxtacrine
33%
Apoptotic Bodies
33%
Aneurysm Progression
33%
Human Carrier
33%
Vascular SMCs
33%
Advanced Development
33%
Medicine and Dentistry
Atherosclerosis
100%
Calreticulin
100%
Efferocytosis
100%
Cyclin Dependent Kinase Inhibitor 2B
100%
Atherosclerotic Plaque
66%
Cardiovascular Disease
33%
Programmed Cell Death
33%
Inflammatory Cytokine
33%
Receptor
33%
Macrophage
33%
Aneurysm
33%
Allele
33%
Genetic Variation
33%
Atherogenesis
33%
Foam Cell
33%
Diseases
33%
Biochemistry, Genetics and Molecular Biology
Cyclin-Dependent Kinase
100%
Calreticulin
100%
CDKN2B
100%
Efferocytosis
100%
Lipid
33%
Allele
33%
Candidate Gene
33%
Macrophage
33%
Genetic Divergence
33%
Genetic Variation
33%
Mouse Model
33%
Inflammatory Cytokine
33%
Foam Cell
33%
Phagocyte
33%
Programmed Cell Death
33%
Immunology and Microbiology
Atherosclerosis
100%
Calreticulin
100%
Cycline
100%
Efferocytosis
100%
Genetic Variation
33%
Allele
33%
Macrophage
33%
Mouse Model
33%
Foam Cell
33%
Inflammatory Cytokine
33%
Phagocyte
33%
Programmed Cell Death
33%
Pharmacology, Toxicology and Pharmaceutical Science
Atherosclerosis
100%
Calreticulin
100%
Cyclin Dependent Kinase Inhibitor 2B
100%
Atherosclerotic Plaque
66%
Cytokine
33%
Mouse Model
33%
Receptor
33%
Aneurysm
33%
Atherogenesis
33%
Cardiovascular Disease
33%
Diseases
33%